Total Revenues for Fiscal 2019 were $127.2 million, up 11% as Compared to 2018 Gross Profit for Fiscal 2019 was $49.7 Million, up 20% as Compared to 2018 Adjusted EBITDA…
Rehovot, Israel, February 5, 2020 — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the fourth quarter…
Execution of Securities Purchase Agreement with FIMI Opportunity Fund, an Existing Strategic Investor, to Support Kamada’s Growth Plans and Execution of Strategic Business Opportunities Rehovot, Israel – January 21, 2020…
Full-Year 2019 Revenue Expected to be Between $126.5 Million and $127.5 Million, in-line with Company’s Prior Revenue Guidance Company Expects Full-Year 2020 Total Revenue to be Between $132 Million and…
Rehovot, Israel, December 16, 2019 — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first patient has been randomized in Europe into its…
Commercial supply of the 12-year contract manufacturing agreement, following the completion of the required tech-transfer project, is expected to commence in early 2023 Based on current market sales volume, the…
REHOVOT, Israel – December 2, 2019 — Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical company, to commercialize…
Total Revenues for Third Quarter and First Nine Months of 2019 were $33.1 Million and $95.1 Million, Respectively, Compared to $15.0 Million and $66.3 Million in the Respective Periods in…
Rehovot, Israel, November 7, 2019 — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the third quarter and…
The Successful Study was Basis for U.S. Food & Drug Administration Approval of KEDRAB® in 2017 Post-Marketing U.S. Pediatric Study Data Expected in 2H ‘2020 Abstract will be Presented at…